The endothelin system and its role in acute myocardial infarction.
暂无分享,去创建一个
[1] N. Perico,et al. The potential of endothelin antagonism as a therapeutic approach , 2004, Expert opinion on investigational drugs.
[2] P. Mulder,et al. Endothelin Antagonism in Experimental Ischemic Heart Failure: Hemodynamic, Structural and Neurohumoral Effects , 2001, Heart Failure Reviews.
[3] M. Pfeffer,et al. Endothelin-A Receptor Antagonism during Acute Myocardial Infarction in Rats , 2000, Cardiovascular Drugs and Therapy.
[4] J. Rouleau,et al. Role of endothelins in congestive heart failure. , 2003, Canadian journal of physiology and pharmacology.
[5] C. O'connor,et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). , 2002, American heart journal.
[6] A. Angelini,et al. Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs. , 2002, Cardiovascular research.
[7] M. Clozel,et al. Entry-Into-Humans Study with Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist , 2002, Journal of cardiovascular pharmacology.
[8] P. Galuppo,et al. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. , 2002, Cardiovascular research.
[9] A. Åsberg,et al. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats , 2002, Basic Research in Cardiology.
[10] M. Clozel,et al. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. , 2002, Journal of the American College of Cardiology.
[11] J. Rouleau,et al. Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril. , 2001, Journal of molecular and cellular cardiology.
[12] J. Rouleau,et al. Long-Term Effects of Nonselective Endothelin A and B Receptor Antagonism in Postinfarction Rat: Importance of Timing , 2001, Circulation.
[13] J. Pernow,et al. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion , 2001, Basic Research in Cardiology.
[14] Y. Kakinuma,et al. Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1&agr; Induced for Impaired Myocardial Energy Metabolism , 2001, Circulation.
[15] F. Ruschitzka,et al. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? , 2001, Journal of the American College of Cardiology.
[16] R. Berger,et al. Effects of Endothelin A Receptor Blockade on Endothelial Function in Patients With Chronic Heart Failure , 2001, Circulation.
[17] D. Mann,et al. Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure , 2001, Circulation.
[18] C. Tortorella,et al. Endothelins stimulate aldosterone secretion from dispersed rat adrenal zona glomerulosa cells, acting through ETB receptors coupled with the phospholipase C-dependent signaling pathway , 2001, Peptides.
[19] O. Gomazkov,et al. Chronic ECE inhibition improve cardiac contractility and pump function via changes in nitric oxide system in rat model of acute myocardial ishemia in vivo , 2001 .
[20] D. Webb,et al. Effects of Estrogen Replacement on Infarct Size, Cardiac Remodeling, and the Endothelin System After Myocardial Infarction in Ovariectomized Rats , 2000, Circulation.
[21] E. Braunwald,et al. Congestive Heart Failure: Fifty Years of Progress , 2000, Circulation.
[22] T. Lüscher,et al. Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.
[23] M. Kinoshita,et al. Chronic effects of an orally active selective endothelin-B-receptor antagonist in experimental congestive heart failure. , 2000, Journal of cardiovascular pharmacology.
[24] P. Mulder,et al. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. , 2000, Circulation.
[25] P. Galuppo,et al. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. , 2000, Cardiovascular research.
[26] J. Dupuis. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. , 2000, The Canadian journal of cardiology.
[27] N. Sharpe,et al. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. , 2000, Circulation.
[28] S. Gottlieb,et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. , 2000, Circulation.
[29] I. Yamaguchi,et al. Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. , 2000, Circulation.
[30] M. Nicholls,et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. , 2000, The American journal of cardiology.
[31] B. Prendergast,et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. , 2000, Circulation.
[32] D. Ivy,et al. Prolonged Endothelin B Receptor Blockade Causes Pulmonary Hypertension in the Ovine Fetus , 1999, American journal of physiology. Lung cellular and molecular physiology.
[33] H. Krum,et al. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction. , 2000, Journal of cardiovascular pharmacology.
[34] A. Matsumori,et al. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist. , 1999, Circulation.
[35] Y. Kakinuma,et al. Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. , 1999, Life sciences.
[36] S. Vanni,et al. Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes. , 1999, Journal of cardiovascular pharmacology.
[37] M. Böhm,et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.
[38] Y. Sugishita,et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. , 1999, Circulation.
[39] G. Hasenfuss,et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. , 1999, Circulation.
[40] M. Yanagisawa,et al. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[41] Y. Sugishita,et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. , 1999, The American journal of physiology.
[42] A. Bauch,et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. , 1999, Hypertension.
[43] E. Woodcock,et al. Inhibition of inositol(1,4,5)Trisphosphate generation by endothelin-1 during postischemic reperfusion: A novel antiarrhythmic mechanism. , 1999, Circulation.
[44] G. Slesak,et al. Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. , 1999, Hypertension.
[45] J. Rouleau,et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. , 1998, Circulation.
[46] Y. Kihara,et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. , 1998, Circulation.
[47] J. Rouleau,et al. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. , 1998, Circulation.
[48] P. Mulder,et al. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. , 1998, Cardiovascular research.
[49] J. Pernow,et al. The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion. , 1998, Cardiovascular research.
[50] G. Moe,et al. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. , 1998, Cardiovascular research.
[51] O. Sejersted,et al. Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide. , 1998, Cardiovascular research.
[52] G. Ertl,et al. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. , 1998, Journal of cardiovascular pharmacology.
[53] C. Wainwright,et al. Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic? , 1998, Cardiovascular research.
[54] D. Stewart,et al. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. , 1998, Cardiovascular research.
[55] J. Tardif,et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. , 1998, American heart journal.
[56] M. Böhm,et al. Endothelin receptors in the failing and nonfailing human heart. , 1998, Circulation.
[57] M. Redfield,et al. Chronic oral endothelin type A receptor antagonism in experimental heart failure. , 1998, Hypertension.
[58] D. Stewart,et al. Chronic endothelin-1 blockade preserves myocardial contractility in dilated cardiomyopathy. , 1998, Journal of cardiovascular pharmacology.
[59] F. Lallemand,et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.
[60] T. Lüscher,et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. , 1997, Circulation.
[61] K. Gallagher,et al. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. , 1997, Circulation.
[62] O. Smiseth,et al. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. , 1997, The American journal of physiology.
[63] Y. Sugishita,et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.
[64] K. Ytrehus,et al. Endothelin-1 can reduce infarct size through protein kinase C and KATP channels in the isolated rat heart. , 1996, Cardiovascular research.
[65] T. LeJemtel,et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.
[66] G. Albertin,et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. , 1996, Hypertension.
[67] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[68] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[69] A. Lerman,et al. Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .
[70] E. Schiffrin,et al. Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Receptor regulation and intracellular Ca2+ modulation. , 1996, Circulation research.
[71] M. J. Ashby,et al. Expression of endothelin peptides and mRNA in the human heart. , 1996, Clinical science.
[72] Meihong Lin,et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. , 1995, The Journal of clinical investigation.
[73] M. Yanagisawa,et al. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. , 1995, Circulation research.
[74] V. Breu,et al. Role of endothelin during reperfusion after ischemia in isolated perfused rat heart. , 1994, Journal of cardiovascular pharmacology.
[75] V. Richard,et al. Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA‐ETB antagonist , 1994, British journal of pharmacology.
[76] M. Polokoff,et al. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.
[77] W. Neidhart,et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. , 1994, The Journal of pharmacology and experimental therapeutics.
[78] G. Lamas,et al. Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril , 1994, Circulation.
[79] C. Thiemermann,et al. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion , 1994, British journal of pharmacology.
[80] R. T. Lie,et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. , 1994, Circulation.
[81] E. Schiffrin,et al. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. , 1994, Circulation research.
[82] K. Weber,et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. , 1993, Cardiovascular research.
[83] G. Grover,et al. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. , 1993, Cardiovascular research.
[84] J. Egido,et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. , 1993, Circulation.
[85] M. Shichiri,et al. Up-regulation of ETB receptor subtype mRNA by angiotensin II in rat cardiomyocytes. , 1993, Biochemical and biophysical research communications.
[86] A. Nogami,et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. , 1993, The Journal of clinical investigation.
[87] A. Davenport,et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. , 1992, Circulation research.
[88] N. Trippodo,et al. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. , 1992, The Journal of pharmacology and experimental therapeutics.
[89] L. Opie,et al. Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. , 1992, Journal of molecular and cellular cardiology.
[90] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[91] T. Schaberg,et al. Endothelin increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar macrophages. , 1991, The American journal of physiology.
[92] T. Watanabe,et al. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. , 1991, Circulation research.
[93] D. Stewart,et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. , 1991, Journal of the American College of Cardiology.
[94] B. Krämer,et al. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. , 1990, The Journal of clinical investigation.
[95] M. Pfeffer,et al. Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.
[96] M. Yanagisawa,et al. INCREASED PLASMA CONCENTRATIONS OF ENDOTHELIN-1 AND BIG ENDOTHELIN-1 IN ACUTE MYOCARDIAL INFARCTION , 1989, The Lancet.
[97] G. Feuerstein,et al. Lethal ischemia due to intracoronary endothelin in pigs. , 1989, The American journal of physiology.
[98] D. Stewart,et al. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. , 1989, Biochemical and biophysical research communications.
[99] M. Bond,et al. Endothelin is a positive inotropic agent in human and rat heart in vitro. , 1989, Biochemical and biophysical research communications.
[100] M. Yanagisawa,et al. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. , 1988, Biochemical and biophysical research communications.
[101] M. Pfeffer,et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.
[102] Smith Pm. Letter: Upper gastrointestinal endoscopy. , 1974, The Lancet.